Importance of ATM gene as a susceptible trait: predisposition role of D1853N polymorphism in breast cancer.
The involvement of ATM gene and specifically, the important role of D1853N polymorphism, as a three-hit hypothesis has been previously reported in an Iranian proband affected with brain tumor and this polymorphism could be screened in her relatives as well. The aim of present study was to investigate the involvement of D1853N polymorphism as a predisposition factor in 129 Iranian patients affected with primary breast cancer and 248 sex- and age-matched healthy controls. Mutant allele-specific PCR amplification (MASA) assay was performed to analyze the D1853N polymorphism in the ATM gene. The frequency of D1853N polymorphism in cases, internal and external controls was 31.0% (40/129), 26.9% (28/104) and 12.5% (18/144), respectively. The frequency of D1853N in total control groups, including normal external control and pedigree internal control, was 18.6% (46/248). The odds ratio was calculated with the logistic regression test, with an estimated relative risk of 2.579 (P=0.005). The significant difference was observed between the patient-carriers of this alteration and external controls (P=0.001). The number of controls harboring D1853N polymorphism was higher in internal control compared to external controls, and the difference was statistically significant (P=0.004). The significant difference was observed between the patient-carriers and external controls and could be considered as a predisposing and diagnostic marker in the population and specifically in the cancer-prone pedigrees.
Mehdipour
Parvin
P
Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran. mehdipor@tums.ac.ir
Mahdavi
Marzieh
M
Mohammadi-Asl
Javad
J
Atri
Morteza
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D064007:Ataxia Telangiectasia Mutated Proteins; D001943:Breast Neoplasms / Q000235:genetics*; D016022:Case-Control Studies; D018797:Cell Cycle Proteins / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D006801:Humans; D007492:Iran; D008875:Middle Aged; D016017:Odds Ratio; D016133:Polymerase Chain Reaction; D020641:Polymorphism, Single Nucleotide; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D025521:Tumor Suppressor Proteins / Q000235:genetics*; D055815:Young Adult
D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D025521:Tumor Suppressor Proteins; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases
Int J Radiat Biol. 1994 Dec;66(6 Suppl):S177-82
7836845
Nat Genet. 1997 Mar;15(3):307-10
9054948
Nat Med. 1997 Oct;3(10):1155-9
9334731
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
5279523
Cancer Res. 1995 Jul 15;55(14):3003-7
7606718
Am J Hum Genet. 2000 Feb;66(2):494-500
10677309
Genes Chromosomes Cancer. 1999 Jul;25(3):212-21
10379867
Med Oncol. 2011 Mar;28(1):7-14
20077038
Hum Mol Genet. 1999 Jan;8(1):69-79
9887333
Ann Oncol. 2009 Mar;20(3):556-63
19073863
Cancer Genet Cytogenet. 1996 Dec;92(2):130-4
8976369
Nat Genet. 1997 Sep;17(1):96-9
9288106
Blood. 1998 May 15;91(10):3920-6
9573030
Cancer Res. 1994 Sep 1;54(17):4586-9
8062246
J Cancer Res Clin Oncol. 2008 Nov;134(11):1173-80
18465141
Adv Cancer Res. 2001;83:209-54
11665719
Oncogene. 1998 Feb 12;16(6):789-96
9488043
Cancer Res. 1994 Dec 1;54(23):6270-4
7954477
Genes Chromosomes Cancer. 1999 Dec;26(4):286-94
10534763
Hum Mutat. 1997;10(2):100-7
9259193